Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Top Cited Papers
- 20 February 2013
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 381 (9873), 1203-1210
- https://doi.org/10.1016/s0140-6736(12)61763-2
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Follicular Lymphoma in the United States: First Report of the National LymphoCare StudyJournal of Clinical Oncology, 2009
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood, 2008
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular LymphomaJournal of Clinical Oncology, 2008
- Current treatment standards and future strategies in mantle cell lymphomaAnnals of Oncology, 2008
- Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology StudyJournal of Clinical Oncology, 2007
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Chemotherapy-induced alopecia: psychosocial impact and therapeutic approachesSupportive Care in Cancer, 2004